Literature DB >> 2193348

Invasive infection with Saccharomyces cerevisiae: report of three cases and review.

J N Aucott1, J Fayen, H Grossnicklas, A Morrissey, M M Lederman, R A Salata.   

Abstract

Saccharomyces cerevisiae (brewer's or baker's yeast) is a common colonizer of human mucosal surfaces, but its role as a clinically important pathogen has been unclear. We report three cases of life-threatening invasive infection with S. cerevisiae resulting in pneumonia, liver abscess and sepsis, and disseminated infection with cardiac tamponade, respectively. A review of the English-language literature reveals 14 other cases of saccharomyces infection in humans. Severe immunosuppression, prolonged hospitalization, prior antibiotic therapy, and/or prosthetic cardiac valves are the settings where saccharomyces infection has been observed. Because Saccharomyces can be a common saprophytic contaminant, biopsy and pathologic confirmation of infection are often necessary for a definitive diagnosis. Amphotericin B is the treatment of choice for serious infections with this organism.

Entities:  

Mesh:

Year:  1990        PMID: 2193348     DOI: 10.1093/clinids/12.3.406

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  26 in total

1.  Use of PCR coupled with electrospray ionization mass spectrometry for rapid identification of bacterial and yeast bloodstream pathogens from blood culture bottles.

Authors:  Erin J Kaleta; Andrew E Clark; Desiree R Johnson; Dulini C Gamage; Vicki H Wysocki; Abdessalam Cherkaoui; Jacques Schrenzel; Donna M Wolk
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

2.  Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains.

Authors:  C Hennequin; A Thierry; G F Richard; G Lecointre; H V Nguyen; C Gaillardin; B Dujon
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

3.  Determination of MICING: a new assay for assessing minimal inhibitory concentration for invasive growth.

Authors:  J Zupan; Z Tomičić; P Raspor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-27       Impact factor: 3.267

4.  Saccharomyces boulardii fungemia caused by treatment with a probioticum.

Authors:  Julie Bjerre Thygesen; Henning Glerup; Britta Tarp
Journal:  BMJ Case Rep       Date:  2012-03-27

5.  Molecular and epidemiological characterization of vaginal Saccharomyces cerevisiae isolates.

Authors:  B Posteraro; M Sanguinetti; G D'Amore; L Masucci; G Morace; G Fadda
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

6.  Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae.

Authors:  J H McCusker; K V Clemons; D A Stevens; R W Davis
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.

Authors:  Y F Berrouane; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Immunological and central nervous system changes in mice suffering from Staphyloccocus aureus and treated with Saccharomyces cerevisiae var. vini living cells.

Authors:  I Ochigava; L Kalandarishvili; M Zhvania
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 9.  Two cases of vaginitis caused by itraconazole-resistant Saccharomyces cerevisiae and a review of recently published studies.

Authors:  Vincenzo Savini; Chiara Catavitello; Assunta Manna; Marzia Talia; Fabio Febbo; Andrea Balbinot; Francesco D'Antonio; Giovanni Di Bonaventura; Claudio Celentano; Marco Liberati; Raffaele Piccolomini; Domenico D'Antonio
Journal:  Mycopathologia       Date:  2008-04-29       Impact factor: 2.574

10.  Pathogenicity of Saccharomyces cerevisiae in complement factor five-deficient mice.

Authors:  J K Byron; K V Clemons; J H McCusker; R W Davis; D A Stevens
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.